CA2435835A1 - Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer - Google Patents
Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer Download PDFInfo
- Publication number
- CA2435835A1 CA2435835A1 CA002435835A CA2435835A CA2435835A1 CA 2435835 A1 CA2435835 A1 CA 2435835A1 CA 002435835 A CA002435835 A CA 002435835A CA 2435835 A CA2435835 A CA 2435835A CA 2435835 A1 CA2435835 A1 CA 2435835A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- amino acid
- group
- acid residues
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26595501P | 2001-02-02 | 2001-02-02 | |
US60/265,955 | 2001-02-02 | ||
PCT/US2002/003201 WO2002062369A2 (en) | 2001-02-02 | 2002-02-04 | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2435835A1 true CA2435835A1 (en) | 2002-08-15 |
Family
ID=23012573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002435835A Abandoned CA2435835A1 (en) | 2001-02-02 | 2002-02-04 | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1365753A2 (ja) |
JP (1) | JP2004521123A (ja) |
AU (1) | AU2002235520A1 (ja) |
CA (1) | CA2435835A1 (ja) |
WO (1) | WO2002062369A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041786B2 (en) | 2001-03-29 | 2006-05-09 | Callisto Pharmaceuticals | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CN100589839C (zh) | 2003-01-28 | 2010-02-17 | 艾恩伍德医药品股份有限公司 | 多肽及包含多肽的药物组合物 |
EP3342420A1 (en) | 2003-06-13 | 2018-07-04 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7494979B2 (en) | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
US8207295B2 (en) | 2008-06-04 | 2012-06-26 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2930674A1 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
PE20151205A1 (es) | 2008-08-15 | 2015-08-31 | Ironwood Pharmaceuticals Inc | Formulaciones que contienen linaclotida para administracion oral |
WO2010027405A2 (en) * | 2008-09-04 | 2010-03-11 | Ironwood Pharmaceuticals, Inc. | Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration |
JP5964589B2 (ja) | 2008-12-03 | 2016-08-03 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcアゴニストの製剤およびその使用方法 |
CA2770077A1 (en) | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
EA201290799A1 (ru) | 2010-02-17 | 2013-03-29 | Айронвуд Фармасьютикалз, Инк. | Лечение желудочно-кишечных расстройств |
RS59978B1 (sr) | 2010-08-11 | 2020-03-31 | Ironwood Pharmaceuticals Inc | Stabilne formulacije linaklotida |
CA2810243C (en) | 2010-09-15 | 2021-04-20 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2013025969A1 (en) | 2011-08-17 | 2013-02-21 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
-
2002
- 2002-02-04 AU AU2002235520A patent/AU2002235520A1/en not_active Abandoned
- 2002-02-04 CA CA002435835A patent/CA2435835A1/en not_active Abandoned
- 2002-02-04 JP JP2002562375A patent/JP2004521123A/ja not_active Withdrawn
- 2002-02-04 EP EP02702137A patent/EP1365753A2/en not_active Withdrawn
- 2002-02-04 WO PCT/US2002/003201 patent/WO2002062369A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2002062369A2 (en) | 2002-08-15 |
AU2002235520A1 (en) | 2002-08-19 |
WO2002062369A3 (en) | 2003-08-28 |
JP2004521123A (ja) | 2004-07-15 |
EP1365753A2 (en) | 2003-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2435835A1 (en) | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer | |
AU745797B2 (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
US5990148A (en) | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | |
US20030220374A1 (en) | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors | |
US20040147581A1 (en) | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | |
EP1397145B1 (en) | Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders | |
US20030212138A1 (en) | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | |
MXPA04010888A (es) | Combinacion de inhibidores de ciclooxigenasa-2 y talidomida para el tratamiento de neoplasia. | |
US20050119262A1 (en) | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent | |
JP2007526328A (ja) | 単独および抗うつ薬と組み合わせた形のCox−2阻害剤によって精神障害を治療または予防するための方法および組成物 | |
KR20040072720A (ko) | 항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 cox-2 억제제의 용도 | |
US20030157061A1 (en) | Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor | |
US20040121961A1 (en) | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer | |
JP2007509968A (ja) | 新形成を治療または予防するためのhsp90阻害剤およびホスホジエステラーゼ阻害剤を含む組み合わせ | |
JP2005500259A (ja) | 癌の治療の薬剤及び方法 | |
US20020035156A1 (en) | Combination therapy in the prevention of cardiovascular disorders | |
JP2006524259A (ja) | Cox−2インヒビターとアロマターゼ・インヒビターとの治療的併用薬 | |
US20070072861A1 (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
JP2006523715A (ja) | 新生物形成の治療のためのcox−2阻害薬とアルキル化型抗新生物剤との組合せ医薬 | |
US20030207846A1 (en) | Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin | |
US20030130334A1 (en) | Methods and compositions for the treatment of psychiatric disorders | |
WO2005020926A2 (en) | Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors | |
US20050004224A1 (en) | Treatment of Alzheimer's disease with the R(-) isomer of a 2-arylpropionic acid non-steroidal anti-inflammatory drug alone or in combination with a cyclooxygenase-2 selective inhibitor | |
MXPA99009495A (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
CZ9903642A3 (cs) | Použití inhibitorů cyklooxygenasy-2 pro prevenci kardiovaskulárních onemocnění |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20080204 |